Please Wait.....

Report

US Cell & Gene Therapy Market - Focused Insights 2023-2028

Market Report I 2023-05-17 I Arizton Advisory & Intelligence

REPORT OVERVIEW

- This report offers market size & forecast data for the cell & gene therapy market in the US. The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies. Cell therapies sourced from mesenchymal stem cells, cell-based immune modulation therapies, and cell/tissue-based products derived from patients' blood are also covered in the report. Tissue-engineered products and tissue grafts/scaffolds with synthetic mechanical structures are excluded from the report's scope. This report provides a comprehensive and current market scenario of the US cell & gene therapy market, including the US cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
- The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023?2028 in the US. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.

MARKET DEFINITION

Cell and gene therapies are part of advanced therapy medicinal products (ATMPs) developed based on genes, tissues, and cells. The introduction of many novel ATMPs in recent years, especially cell and gene therapies, changed the treatment dynamics of many complex and challenging diseases like cancer and genetic disorders. In recent years, growth in the cell and gene therapy market has fueled some high-profile mergers and acquisitions, including bluebird bio/BioMarin, Bristol-Myers Squibb/Celgene/Juno Therapeutics, Gilead Sciences/Kite, Novartis/AveXis and the CDMO CELLforCURE, Roche/Spark Therapeutics, and Smith & Nephew/Osiris Therapeutics. Over 20 cell therapy launches and as many as 31 gene therapies launches-including more than 29 Adeno-associated viruses (AAV) therapies-are projected to be approved by 2024.

KEY HIGHLIGHTS

- The US cell and gene therapy market was valued at $3.22 billion in 2022 and is projected to reach $25.58 billion in 2028, with a compound annual growth rate (CAGR) of 41.25%, during the study period.
- Among all commercial cell & gene therapies, Zolgensma is the first and only product to achieve the blockbuster drug tag. Zolgensma generated a revenue of $1.37 billion in 2022 and could reach around $5.00 billion by 2026.
- Drug developers are prioritizing developing and commercializing CAR-T cell-based gene therapies. Globally, more than 1,000 clinical trials are being conducted on CAR T-cell therapies, of which at least 500 clinical trials are for cancer alone. Kymriah (Novartis), Yescarta (Gilead Sciences), Tecartus (Gilead Sciences), Breyanzi (Bristol Myers Squibb), Abecma (Bristol Myers Squibb), and Carvykti (Janssen Biotech / Legend Biotech) are the commercial CAR-T therapies available in the market.
- In 2022, the US was the fastest-growing market with a high market share in North America. The market is driven by an increased target patient population, regulatory body support, and higher access to healthcare due to well-established healthcare infrastructure.
- The Food and Drug Administration (FDA) has approved over twenty cell and gene therapy drugs. Still, the new product pipeline has approximately 365 investigational therapies, with more than half of these in Phase 2 clinical trials. Oncology and rare diseases remain the top areas targeted by gene therapies from preclinical through pre-registration.
- Approximately 1,604 clinical trials are under investigation for various cell and gene therapies in the US. This increase could be because of increased funding for cell and gene therapy. The industry-sponsored trials are continued to dominate with a share of 51.81%.
- Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the US cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of a large pool of target patient populations with chronic diseases such as cancer, genetic and rare diseases, and other complex disorders.

VENDOR ANALYSIS

- Novartis
- Gilead Sciences
- Amgen
- Roche
- bluebird bio
- Legend Biotech
- Bristol-Myers Squibb
- UniQure
- Ferring Pharmaceuticals
- Organogenesis
- Vericel Corp
- Dendreon
- Mallinckrodt
- Enzyvant
- Avita Medical
- Fibrocell
- 4DMT
- Abeona Therapeutics
- Autolus Therapeutics
- Candel Therapeutics
- Castel Creek Biosciences
- Cellectis
- Evox Therapeutics
- Freeline Therapeutics
- Generation Bio
- Gensight Biologics
- Krystal Biotech
- MeiraGTx
- Pfizer
- Gamida Cell
- Iovance Biotherapeutics
- Sarepta Therapeutics
- PTC Therapeutics
- Atara Bio
- Adaptimmune
- CRISPR Therapeutics
- Carsgen Therapeutics
- Orchard Therapeutics
- Biomarin
- StemCyte
- Helixmith

REPORT HIGHLIGHTS

PRODUCT SEGMENTATION & FORECAST
- Product type
? Cell therapy
? Gene therapy
- Application type
? Oncology
? Genetic Disorders
? Dermatology
? Musculoskeletal
? Others
- End-user type
? Hospitals
? Cancer Care Centers
? Others

MARKET STRUCTURE
- Approved Cell & Gene Therapies
- Pipeline Analysis
- Clinical Trial Analysis
- Market Dynamics
- Competitive Landscape of Cell & Gene Therapies
- Key Vendors
- Other Prominent Vendors

PRICING & REIMBURSEMENT SCENARIO
- Pricing, Reimbursement, and Market Access
- Contract Manufacturing Organizations

APPENDIX
- Research Methodology
- Abbreviations
- About Arizton

CHAPTER - 1: Cell & Gene Therapy Market Overview
- Executive Summary
- Introduction
- Key Findings
- Key Developments

CHAPTER - 2: Cell & Gene Therapy Market Segmentation Data
- US: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
o Product type
o Application type
o End-user type

CHAPTER - 3: Cell & Gene Therapy Prospects & Opportunities
- Cell & Gene Therapy Market Drivers
- Cell & Gene Therapy Market Trends
- Cell & Gene Therapy Market Constraints

CHAPTER - 4: Cell & Gene Therapy Industry Overview
- Cell & Gene Therapy - Marketed Drugs Overview
- Cell & Gene Therapy - Pipeline Drugs Overview
- Cell & Gene Therapy - Competitive Landscape
- Cell & Gene Therapy - Key Players
- Cell & Gene Therapy - Key Company Profiles
- Cell & Gene Therapy - Mergers & Acquisitions
- Cell & Gene Therapy - Key Strategic Recommendations

CHAPTER - 5: Pricing and Reimbursement Scenario
- Pricing, Reimbursement and Market Access
- Contract Manufacturing Organizations (CMOs)

CHAPTER - 6: Appendix
- Research Methodology
- Abbreviations
- About Arizton

LIST OF EXHIBITS

Exhibit 1: Projected Revenue of Cell & Gene Therapy Market in the US (2022 - 2028)
Exhibit 2: Projected Revenue of Cell & Gene Therapy Market in the US by Product Type
(2022 - 2028)
Exhibit 3: Projected Revenue of Cell & Gene Therapy Market in the US by Application Type
(2022 - 2028)
Exhibit 4: Projected Revenue of Cell & Gene Therapy Market in the US by End-user Type
(2022 - 2028)
Exhibit 5: Marketed Drugs Overview in Cell & Gene Therapy Market
Exhibit 6: Pipeline Drugs Overview in Cell & Gene Therapy Market

LIST OF TABLES

Table 1: Key Market Trends in Cell & Gene Therapy Market
Table 2: Key Market Enablers in Cell & Gene Therapy Market
Table 3: Key Market Constraints in Cell & Gene Therapy Market
Table 4: Recent Approvals in Cell & Gene Therapy Market
Table 5: Near-term Approvals in Cell & Gene Therapy Market
Table 6: Strategic Recommendations in Cell & Gene Therapy Market
Table 7: Mergers & Acquisitions in Cell & Gene Therapy Market
Table 8: Pricing & Reimbursement of Cell & Gene Therapy Market

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.